Bick RL. Antiphospholipid thrombosis syndromes. Clin Appl Thromb Hemost 2001; 7:241–258.
Article
CAS
Google Scholar
Soltesz P, Veres K, Lakos G, Kiss E, Muszbek L, Szegedi G. Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients. Lupus 2003; 12:302–307.
Article
CAS
Google Scholar
De Laat B, Mertens K, de Groot PG. Mechanisms of disease: antiphospholipid antibodies—from clinical association to pathologic mechanism. Nat Clin Pract Rheumatol 2008; 4:192–199.
Article
Google Scholar
Oosting JD, Derksen RH, Bobbink IW, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993; 81:2618–2625.
Article
CAS
Google Scholar
Atsumi T, Amengual O, Yasuda S, Koike T. Antiprothrombin antibodies— are they worth assaying?Thromb Res 2004; 114 (5–6): 533–538.
Van Heerde WL, Lap P, Schoormans S, de Groot PG, CPM Reutelingsperger, Vroom TM. Localization of annexin A5 in human tissue. Annexins 2004; 1:37–43.
Google Scholar
De Laat B, RHWM Derksen, Mackie IJ, Roest M, Schoormans S, Woodhams BJ, et al. Annexin A5 polymorphism (-1C→T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann Rheum Dis 2006; 65:1468–1472.
Article
Google Scholar
Rand JH, Wu XX, Quinn AS, Chen PP, McCrae KR, Bovill EG, et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol 2003; 163:1193–1200.
Article
CAS
Google Scholar
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
Article
CAS
Google Scholar
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295–306.
Article
CAS
Google Scholar
Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. Lupus 2002; 11:269–275.
Article
CAS
Google Scholar
Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC. Proposals for the measurement of anti-β2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004; 2:1860–1862.
CAS
PubMed
Google Scholar
Bizzaro N, Tonutti E, Villalta D, Tampoia M, Tozzoli R. Prevalence and clinical correlation of anti-phospholipid-binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages. Arch Pathol Lab Med 2005; 129:61–68.
PubMed
Google Scholar
Atsumi T, Koike T. Antiprothrombin antibody: why do we need more assays? Lupus 2010; 19:436–439.
Article
CAS
Google Scholar
Theodoridou A, Bertolaccini M, Hamid C, Khamashta MA, Hughes GRV. The value of testing for antiphospholipid antibodies, other than aCL and LA, in systemic lupus erythematosus patients with thrombosis. Arthritis Rheum 2002; 46 (Suppl): S50.
Hsieh K, Knöbl P, Rintelen C, Kyrle PA, Quehenberger P, Bialonczyk C, et al. Is the determination of anti-beta2 glycoprotein I antibodies useful in patients with venous thromboembolism without the antiphospholipid syndrome? Br J Haematol 2003; 123:490–495.
Article
CAS
Google Scholar
Puurunen M, Vaarala O, Julkunen H, Aho K, Palosuo T. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1996;80:16–22.
Article
CAS
Google Scholar
Bertolaccini ML, Atsumi T, Khamashta MA, Amengual O, Hughes GRV. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol 1998; 25:1104–1108.
CAS
PubMed
Google Scholar
Muñoz Rodríguez FJ, Reverter JC, Font J, Tàssies D, Cervera R, Espinosa G, et al. Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome. Haematologica 2000; 85:632–637.
PubMed
Google Scholar
Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, et al. Anti-prothrombin antibodies combined with lupus anticoagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol 2001; 114:647–654.
Article
CAS
Google Scholar
Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76:916–924.
CAS
PubMed
Google Scholar
Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996; 75:721–724.
Article
CAS
Google Scholar
Swadzba J, De Clerck LS, Stevens WJ, Bridts CH, Van Cotthem KA, Musial J, et al. Anticardiolipin, anti-β2-glycoprotein I, antiprothrombin antibodies and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol 1997; 24:1710–1715.
CAS
PubMed
Google Scholar